106 related articles for article (PubMed ID: 27362789)
1. Design and screening of a chimeric survivin-specific nanobody and its anticancer activities in vitro.
Zhang N; Guo H; Zheng W; Wang T; Ma X
Anticancer Drugs; 2016 Oct; 27(9):839-47. PubMed ID: 27362789
[TBL] [Abstract][Full Text] [Related]
2. Targeting survivin with prodigiosin isolated from cell wall of Serratia marcescens induces apoptosis in hepatocellular carcinoma cells.
Yenkejeh RA; Sam MR; Esmaeillou M
Hum Exp Toxicol; 2017 Apr; 36(4):402-411. PubMed ID: 27334973
[TBL] [Abstract][Full Text] [Related]
3. Characterization and applications of Nanobodies against human procalcitonin selected from a novel naïve Nanobody phage display library.
Yan J; Wang P; Zhu M; Li G; Romão E; Xiong S; Wan Y
J Nanobiotechnology; 2015 May; 13():33. PubMed ID: 25944262
[TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of a novel nanobody against human placental growth factor to modulate angiogenesis.
Arezumand R; Mahdian R; Zeinali S; Hassanzadeh-Ghassabeh G; Mansouri K; Khanahmad H; Namvar-Asl N; Rahimi H; Behdani M; Cohan RA; Eavazalipour M; Ramazani A; Muyldermans S
Mol Immunol; 2016 Oct; 78():183-192. PubMed ID: 27648860
[TBL] [Abstract][Full Text] [Related]
5. Effects of AFP gene silencing on Survivin mRNA expression inhibition in HepG2 cells.
Fang ZL; Fang N; Han XN; Huang G; Fu XJ; Xie GS; Wang NR; Xiong JP
Genet Mol Res; 2015 Apr; 14(2):3184-90. PubMed ID: 25966084
[TBL] [Abstract][Full Text] [Related]
6. Novel multi-substituted benzyl acridone derivatives as survivin inhibitors for hepatocellular carcinoma treatment.
Zhang B; Wang N; Zhang C; Gao C; Zhang W; Chen K; Wu W; Chen Y; Tan C; Liu F; Jiang Y
Eur J Med Chem; 2017 Mar; 129():337-348. PubMed ID: 28237663
[TBL] [Abstract][Full Text] [Related]
7. [The effect of antisense survivin-liposome complex on cell growth, apoptosis and cell cycle in hepatocellular carcinoma cells].
Dai DJ; Wu D; Meng H; Lu CD
Zhonghua Zhong Liu Za Zhi; 2005 Oct; 27(10):581-5. PubMed ID: 16438864
[TBL] [Abstract][Full Text] [Related]
8. [Effect of inhibiting survivin expression with antisense oligodeoxynucleotides on sensitivity of hepatocellular carcinoma cell lines HepG2 and HepG2/ADM to adriamycin].
Dai DJ; Lu CD; Guo JM; Zhang J
Ai Zheng; 2005 Aug; 24(8):951-7. PubMed ID: 16086872
[TBL] [Abstract][Full Text] [Related]
9. Designing and constructing a phage display synthesized single domain antibodies library based on camel VHHs frame for screening and identifying humanized TNF-α-specific nanobody.
Nie J; Ma X; Hu F; Miao H; Feng X; Zhang P; Han MH; You F; Yang Y; Zhang W; Zheng W
Biomed Pharmacother; 2021 May; 137():111328. PubMed ID: 33571835
[TBL] [Abstract][Full Text] [Related]
10. siRNA targeting survivin inhibits the growth and enhances the chemosensitivity of hepatocellular carcinoma cells.
Liu W; Zhu F; Jiang Y; Sun D; Yang B; Yan H
Oncol Rep; 2013 Mar; 29(3):1183-8. PubMed ID: 23254641
[TBL] [Abstract][Full Text] [Related]
11. Construction of a synthetic phage-displayed Nanobody library with CDR3 regions randomized by trinucleotide cassettes for diagnostic applications.
Yan J; Li G; Hu Y; Ou W; Wan Y
J Transl Med; 2014 Dec; 12():343. PubMed ID: 25496223
[TBL] [Abstract][Full Text] [Related]
12. [Preparation of recombinant HIV-TATm-survivin (T34A) protein and its pro-apoptosis activity to cancer cells in vitro].
Zheng WY; Ma XY; Wei DZ; Wang JZ; Liu QH; Ma YS; Yang SL
Sheng Wu Gong Cheng Xue Bao; 2006 Mar; 22(2):285-92. PubMed ID: 16607958
[TBL] [Abstract][Full Text] [Related]
13. Involvement of mTOR and survivin inhibition in tamoxifen-induced apoptosis in human hepatoblastoma cell line HepG2.
Guo R; Wang T; Shen H; Ge HM; Sun J; Huang ZH; Shu YQ
Biomed Pharmacother; 2010 Apr; 64(4):249-53. PubMed ID: 19931998
[TBL] [Abstract][Full Text] [Related]
14. [Down-regulation of mTOR activity and survivin expression during tamoxifen-induced apoptosis in hepatoblastoma cells].
Guo RH; Wang TS; Chen XF; Huang ZH; Shu YQ
Zhonghua Zhong Liu Za Zhi; 2010 Dec; 32(12):903-6. PubMed ID: 21223797
[TBL] [Abstract][Full Text] [Related]
15. A new survivin tracer tracks, delocalizes and captures endogenous survivin at different subcellular locations and in distinct organelles.
Beghein E; Van Audenhove I; Zwaenepoel O; Verhelle A; De Ganck A; Gettemans J
Sci Rep; 2016 Aug; 6():31177. PubMed ID: 27514728
[TBL] [Abstract][Full Text] [Related]
16. Iodoacetyl-functionalized pullulan: A supplemental enhancer for single-domain antibody-polyclonal antibody sandwich enzyme-linked immunosorbent assay for detection of survivin.
Matsushita T; Arai H; Koyama T; Hatano K; Nemoto N; Matsuoka K
Bioorg Med Chem Lett; 2017 Nov; 27(21):4844-4848. PubMed ID: 28974337
[TBL] [Abstract][Full Text] [Related]
17. Positive charge in the complementarity-determining regions of synthetic nanobody prevents aggregation.
Zhong Z; Yang Y; Chen X; Han Z; Zhou J; Li B; He X
Biochem Biophys Res Commun; 2021 Oct; 572():1-6. PubMed ID: 34332323
[TBL] [Abstract][Full Text] [Related]
18. [Construction and application of a noval gene-target therapy system in hepatocellular carcinoma].
Zhang G; Liu T; Wang Z
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2012 Jun; 29(3):563-7, 592. PubMed ID: 22826959
[TBL] [Abstract][Full Text] [Related]
19. Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable Survivin antagonist.
Yan H; Thomas J; Liu T; Raj D; London N; Tandeski T; Leachman SA; Lee RM; Grossman D
Oncogene; 2006 Nov; 25(52):6968-74. PubMed ID: 16702945
[TBL] [Abstract][Full Text] [Related]
20. A nanobody directed to a functional epitope on VEGF, as a novel strategy for cancer treatment.
Farajpour Z; Rahbarizadeh F; Kazemi B; Ahmadvand D
Biochem Biophys Res Commun; 2014 Mar; 446(1):132-6. PubMed ID: 24569074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
